RNA (Atrium Therapeutics) Total Long-Term Assets: $6.80 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.65
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Total Long-Term Assets?

Atrium Therapeutics RNA +2.61% 12 Total Long-Term Assets is $6.80 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Atrium Therapeutics's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $6.80 Mil.

Atrium Therapeutics Total Long-Term Assets Related Terms

Atrium Therapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Total Long-Term Assets Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Long-Term Assets
9.44 6.70 5.51

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial 6.70 0.00 6.28 5.51 6.80
RNA
12GF Score
Atrium Therapeutics Inc RNA
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $6.80 Mil mean?
Atrium Therapeutics (RNA) has a Total Long-Term Assets of $6.80 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Total Long-Term Assets too high?
Atrium Therapeutics' current Total Long-Term Assets is $6.80 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Total Long-Term Assets compare to CNTN and QTTB?
Atrium Therapeutics' Total Long-Term Assets of $6.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Total Long-Term Assets is $6.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Total Long-Term Assets of $6.80 Mil. The current Total Long-Term Assets is $6.80 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Total Long-Term Assets is $6.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.65
Price